Issues lobbied + lobbyists (4)
BUD — Budget/Appropriations
FY26 and FY27 appropriations for the National Breast and Cervical Cancer Early Detection Program FY26 and FY27 appropriations for breast cancer research FY26 and FY27 appropriations for cancer prevention and control
Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
INS — Insurance
Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3037/S.1500); a bill prohibiting group health plans and health insurance issuers offering group or individual health insurance coverage from imposing cost-sharing requirements with respect to diagnostic and supplemental breast examinations Implementation of the Affordable Care Act Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging Policies related to coverage of preventive services with no cost-sharing Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46. Protect patients from substandard and junk insurance products Implementation of One Big Beautiful Bill Act (H.R.1) Policies related to coverage for breast cancer treatments, including breast or chest wall surgical reconstructions Comments on Proposed Rule: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P)
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
MMM — Medicare/Medicaid
Medicare coverage policy for breast cancer treatments and services Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid Medicare coverage policy for drugs and drug pricing Medicare Drug Pricing Negotiation implementation Preserving and expanding access to Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act H.R. 2048, Metastatic Breast Cancer Access to Care Act Submission of Information about Selected Drugs and Their Therapeutic Alternatives for Medicare Drug Price Negotiation Comments on CMS-5546-P: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model Comments on RE: CMS-5545-P: Global Benchmark for Efficient Drug Pricing (GLOBE) Model
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Policies related to PBM and drug cost transparency Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.2381/S. 1866) Policies related to the availability and patient awareness of breast cancer risk assessments H.R. 4541, the EARLY Act Reauthorization of 2025 Comments RE: HHS Health Sector AI RFI Comments RE: Solicitation of Proposals for New and Modified Safe Harbors and Special Fraud Alerts OIG-1125-N, (Annual Solicitation)
Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE